A Phase 1/2, Open-label, Multicenter, Non-Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Burosumab In Pediatric Patients From Birth To <1 Year Of Age With Chromosome-Linked Hypophosphatemia X (XLH)
A Phase 1/2, Open-label, Multicenter, Non-Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Burosumab In Pediatric Patients From Birth To <1 Year Of Age With Chromosome-Linked Hypophosphatemia X (XLH)